4.41 -0.04 (-0.9%) | 04-26 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 5.66 | 1-year : | 6.23 |
Resists | First : | 4.85 | Second : | 5.34 |
Pivot price | 4.79 | |||
Supports | First : | 4.05 | Second : | 3.37 |
MAs | MA(5) : | 4.49 | MA(20) : | 4.78 |
MA(100) : | 4.74 | MA(250) : | 3.87 | |
MACD | MACD : | -0.2 | Signal : | -0.1 |
%K %D | K(14,3) : | 19.2 | D(3) : | 16.8 |
RSI | RSI(14): 40.7 | |||
52-week | High : | 5.69 | Low : | 1.83 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ SVRA ] has closed above bottom band by 15.9%. Bollinger Bands are 39.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 4.52 - 4.55 | 4.55 - 4.57 |
Low: | 4.29 - 4.33 | 4.33 - 4.36 |
Close: | 4.36 - 4.41 | 4.41 - 4.45 |
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Thu, 25 Apr 2024
Savara (NASDAQ:SVRA) Trading Down 6.6% - MarketBeat
Wed, 24 Apr 2024
Jennison Associates LLC Increases Stock Position in Savara Inc (NASDAQ:SVRA) - MarketBeat
Fri, 22 Mar 2024
Savara Announces New Employment Inducement Grant - Business Wire
Thu, 14 Mar 2024
Savara Inc (SVRA) is down -16.10% in a Week, Should You Accumulate? - InvestorsObserver
Wed, 06 Mar 2024
Savara to Present at the Barclays 26th Annual Global Healthcare Conference - Business Wire
Tue, 05 Mar 2024
Is Savara Inc (SVRA) Stock About to Get Hot Tuesday? - InvestorsObserver
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 138 (M) |
Shares Float | 81 (M) |
Held by Insiders | 6.1 (%) |
Held by Institutions | 81.2 (%) |
Shares Short | 3,700 (K) |
Shares Short P.Month | 2,890 (K) |
EPS | -0.34 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 1.01 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -23.4 % |
Return on Equity (ttm) | -44.1 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -0.43 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -51 (M) |
Levered Free Cash Flow | -28 (M) |
PE Ratio | -13.37 |
PEG Ratio | 0 |
Price to Book value | 4.32 |
Price to Sales | 0 |
Price to Cash Flow | -11.94 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |